https://www.selleckchem.com/products/ri-1.html
In patients with SCC-Ag ≥ 4 ng/mL, not SCC-Ag less then 4 ng/mL before treatment, post-treatment SCC-Ag level (≥ 1.5 ng/mL vs. less then 1.5 ng/mL) showed significant differences in 3-year RFS (65.5% vs. 45.0%, p less then 0.001) and OS (78.5% vs. 55.4%, p less then 0.001). In 66 recurrent patients, patients with SCC-Ag ≥ 4 ng/mL at recurrence showed a significantly lower OS rate than others (59.5% vs. 33.0%, p = 0.041). CONCLUSIONS SCC-Ag level after treatment and at recurrence was useful for predicting recurrence and survival onl
Curtir
Comentario
Compartilhar
